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Myocardial Metabolism
It has been known for many years that myocardial per-
formance is determined by a complex series of biochemical
reactions that modulate contractility, electrophysiologic events
and cellular viability. However, in vivo assessment of in-
termediary metabolism of the myocardium has been difficult
to accomplish. Cardiovascular imaging predominantly pro-
vides insights into the structure , configuration and function
of the heart, great vessels and coronary arteries, but not
myocardial metabolism. Production of high energy phos-
phates and utilization of cardiac proteins are regulated on a
beat to beat basis by these metabolic factors (I). Because
energy reserves within the heart are severely limited, the
heart is heavily dependent on a continuous supply of re-
quired substrates from the plasma to maintain energy pro-
duction . For example, the total cardiac stores of high energy
phosphates are depleted very rapidly and glycogen and tri-
glycerides are adequate for only a few minutes. In addition
to the necessity for substrates, oxygen must be available
because adenosine triphosphate (ATP) production by an-
aerobic glycolysis is limited to no more than about 5% of
normal energy production. Myocardial metabolism is reg-
ulated to maintain production of high energy phosphates and
contractility despite dramatic variations in the availability
of critical substrates such as carbohydrates. lipids and amino
acids . The metabolic diversity of the heart allows a wide
spectrum of substrates to be oxidized for energy production.
Substrate uptake and oxidation respond to augmented car-
diac work in proportion to the needs of the myocardium.
Thus . metabolic and functional changes that jeopardize cell
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survival occur only when coronary blood flow is diminished
to the level that oxygen availability and removal of meta-
bolic byproducts are compromised excessively.
Positron Emission Tomograph y
At present . the major technique that has been utilized to
evaluate myocardial metabolism is positron emission to-
mography (PET) (2) . There have been two general ap-
proaches that have evolved for tomographic assessment of
myocardial metabolism by positron emission tomography.
The first involves incorporation of positron-emitting radio-
nuclides, such as carbon-II or nitrogen-13, into physiologic
substrates. There are no specific assumptions concerning
the transport or metabolism of these radiopharmaceuticals
because they behave chemically in a fashion identical to the
native substrate .
The second approach involves the utilization of radio-
labeled analogs of common substrates. These radiophar-
maceuticals are not metabolized in the identical manner as
the true physiologic substrate. Compounds are designed so
that they become metabolically trapped in tissue by virtue
of being refractory to the actions of the enzymes normall y
controlling metabolism of the natural substrate. Such ana-
logs frequently contain longer-li ved positron-emitting radio-
nuclides , such as fluorine-IS, so that their blood clearance
can be completed before tomographic imaging .
Initial studies have employed fluorine-18 fluorodeoxy-
glucose and carbon-II palmitate for the measurement of
exogenous glucose and free fatty acid utilization by the
myocardium. These positron techniques have been com-
bined with evaluation of myocardial blood flow using dif-
fusible tracers. such as rubidium-82 and nitrogen-13 am-
monia, to evaluate the relation s of regional myocardial
metabolism and flow (2.3). These metabolic radiopharma-
ceuticals and positron emission tomography have provided
important insights into the pathophysiology of ischemic heart
disea se. Furthermore . the effects of short-term interventions
such as coronary thrombolysis have been characterized by
positron emission tomographic studies (4). Of interest. tom-
ographic imaging with carbon-I l palmitate has been shown
to differentiate ischemic from idiopathic cardiomyopathies
(5) , Lastly. in patients with Duchenne's muscular dystro-
phy , there is evidence of a localized myocardial metabolic
abnormality that is unique to this rare cardiomyopathy (6).
These studies have demonstrated the potential clinical utility
of positron emission tomography and in vivo metabolic stud-
ies in the evaluation of various forms of cardiomyopathy.
Nuclear Magnetic Resonance Spectroscopy
Nuclear magnetic resonance (NMR) initially was devel-
oped as a chemical spectroscopic technique to ascertain
molecular structures. Thereafter, high resolution nuclear
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magnetic resonance spectroscopy was applied to biologic
systems such as cell cultures and excised organs (7,8). How-
ever, recent advances in this field, as exemplified by the
innovative work described by Whitman et al. (9) in this
issue of the Journal, demonstrate that nuclear magnetic res-
onance spectroscopic methods now can be applied to the
intact human for in vivo metabolic studies.
At present, clinical nuclear magnetic resonance imaging
is limited to protons because they represent the most abun-
dant and sensitive nuclei. Images are based on the spatial
distribution of the relaxation times (TI and T2) and proton
density (7,8). However, there are three biochemically im-
portant nuclei which also are nuclear magnetic resonance-
sensitive and of major interest in terms of myocardial me-
tabolism: phosphorus-31, carbon-13 and sodium-23 (10,11).
The phosphorus- 31 nuclear magnetic resonance spectrum
contains well defined peaks for inorganic phosphate, phos-
phocreatine and the three peaks of ATP. The area under
each peak is proportional to the concentration of each com-
pound. The distance between the inorganic phosphate and
phosphocreatine peaks can be used to derive the intracellular
hydrogen ion concentration (pH). From a biologic perspec-
tive, these nuclei are far more interesting than protons, but
technical factors limit our ability to study these nuclei in
situ. For example, at the same field strength, the relative
sensitivity ofphosphorus-31 is 6.7 x 10- 2 compared with
protons. Furthermore, the phosphorus concentration is sub-
stantially lower than that of protons, thus giving a nuclear
magnetic resonance sensitivity to phosphorus-31 in tissues
of at least 10- 5 less than for protons (12,13).
Phosphorus-3! versus carbon-13 and sodium-23 nu-
clear magnetic resonance spectroscopy. Phosphorus-31
nuclear magnetic resonance spectroscopy represents an im-
portant technique for studying myocardial metabolic pro-
cesses for several reasons. First, the major sources of energy
in the heart for cellular function contain phosphorus. Sec-
ond, the ability of cells to sustain adequate levels of high
energy phosphates is an excellent marker of metabolic in-
tegrity (11).
The relative nuclear magnetic resonance sensitivities of
carbon-13 and sodium-23 compared with protons are 1.6
x 10- 2 and 9. I x 10- 2, respectively. Of note, there are
two substantial differences between phosphorus-31 and car-
bon-13 nuclear magnetic resonance spectroscopy (11). First,
phosphorus-31 is 100% naturally abundant, compared with
I% for carbon-I 3. This means that all nuclei contribute to
the nuclear magnetic resonance signal of phosphorus, but
only I% of the carbon nuclei are detectable by nuclear
magnetic resonance. Because of this, it is often necessary
to administer substrates that have been selectively enriched
with carbon-13 (13). Second, because of the strong inter-
action between the carbon and hydrogen nuclei, there is
frequently dispersion of the carbon-13 signal into multiple
peaks, each at reduced intensity. Thus, it is often necessary
to utilize special decoupling techniques.
Important biochemical data also can be obtained from
carbon-13 and sodium-23 nuclear magnetic resonance stud-
ies. Using enriched precursors, carbon-I 3 nuclear magnetic
resonance allows evaluation of metabolic processes such as
the deposition and utilization of glycogen. The intensities
of glycerol, choline and fatty acid carbon-13 peaks provide
insights into the relative concentrations of tissue triglycer-
ides and lactates (13, 14).
Experimental studies. Early studies of nuclear mag-
netic resonance to evaluate metabolic processes in the heart
involved excised tissue samples placed in sample tubes;
thus, the spectra were not obtained under physiologic con-
ditions. Recently, studies have been performed on intact
organs maintained under physiologic conditions in tissue
baths or with perfused organs, such as the Langendorff
preparation (7,10). This series of investigations has pro-
vided important insights into high energy phosphate metab-
olism during myocardial ischemia, the effects of cardio-
plegic agents and the effects of various cardiac drugs.
Recently, in vivo nuclear magnetic resonance techniques
suitable to monitor cardiac metabolism in living animals
have been described. Neurohr et al. (15,16) demonstrated
the feasibility of studying cardiac metabolism in the guinea
pig instrumented with a specially designed implanted car-
diac surface coil to detect and localize nuclear magnetic
resonance signals. In the in vivo carbon-13 studies, the
incorporation of carbon-13 glucose into myocardial glyco-
gen, the degradation of carbon-13-labeled glycogen during
anoxia, the incorporation of carbon-13 acetate into gluta-
mate and glutamine and the effects of insulin on glucose-
stimulated glycogen synthesis were evaluated. Similarly, in
terms of the phosphorus-31 studies, the rate of depletion
and recovery of high energy phosphates and inorganic phos-
phates and the time course of pH changes were assessed
during and after anoxia.
Clinical studies. Since 1981, there has been a series of
clinical reports in patients with muscular disorders dem-
onstrating the potential use of phosphorus-31 nuclear mag-
netic resonance spectroscopy in evaluation of muscle me-
tabolism. Specifically, using a horizontal small bore nuclear
magnetic resonance spectrometer, abnormalities in high en-
ergy phosphate metabolism have been demonstrated in pa-
tients with McArdle's syndrome (17), mitochondrial my-
opathy (18) and Duchenne' s muscular dystrophy (19).
McArdle's syndrome is an inborn error of metabolism
caused by the lack of glycogen phosphorus activity in skel-
etal muscle and should be considered in the differential
diagnosis of muscular weakness. In one study (17), a patient
with McArdle's syndrome was shown to be abnormal on
the basis of no decrease in intramuscular pH and an exces-
sive reduction of phosphocreatine in response to exercise.
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Both of these responses are predictable because of the in-
ability of the abnormal muscle to break down glycogen and
generate lactic acid as a consequence of phosphorylase de-
ficiency. Subsequently, phosphorus-3l nuclear magnetic
resonance spectroscopy was also applied to the investigation
of cerebral metabolism in newborn infants exposed to hy-
poxia (20). These studies demonstrated markedly abnormal
phosphorus-31 nuclear magnetic resonance spectra, which,
in some cases, antedated the development of clinical or
anatomic changes (cyst formation).
Studies in adult head. The studies just described all were
limited to the limbs of adults or the heads of infants and
were performed in relatively small bore magnets. Nuclear
magnetic resonance spectroscopy requires high magnetic
field strengths in the 1 to 15 tesla range and excellent field
homogeneity (better than I part per million within the region
of examination) (21). These criteria are not easy to attain
in the whole body nuclear magnetic resonance systems re-
quired for cardiac imaging of the adult. However, by virtue
of recent advances in nuclear magnetic resonance instru-
mentation, Bottomley et al. (21) demonstrated that phos-
phorus-31 and carbon-I 3 spectra of the human head can be
obtained using surface coil techniques. In fact, they were
able to demonstrate that high resolution proton nuclear mag-
netic resonance imaging could be performed on the same
instrument as used for nuclear magnetic resonance spec-
troscopy . In addition, preliminary studies from Maudsley
(12) and Hilal (22) and coworkers have demonstrated the
feasibility of imaging the spatial distributions of phospho-
rus-31 and sodium-23 in the brain with resolutions ap-
proaching those of positron emission tomography, but with
far longer acquisition times (up to several hours). Whether
these findings can be extrapolated to other organs such as
the human heart remains to be determined.
Present study of infant myocardium. The accompa-
nying article by Whitman et al. (9) is the first demonstration
ofphosphorus-3i nuclear magnetic resonance spectroscopy
of the human myocardium in situ and the feasibility of op-
timizing therapy (for example, dietary) with nuclear mag-
netic resonance methods. This study demonstrates a marked
abnormality in high energy phosphate metabolism in an
infant with an idiopathic cardiomyopathy and represents an
important step in the development of nuclear magnetic res-
onance techniques for studying human myocardial metab-
olism. As pointed out by the authors , this patient was an
optimal candidate for this type of analysis because she could
be studied in a relatively small bore (27 em) high field
strength (1.9 tesla) magnet system . She also had evidence
of marked left ventricular hypertrophy, which should im-
prove the myocardial signal compared with adjacent struc-
tures . Lastly, considering the patient's age, overlying skel-
etal muscle development was minimal and thus unlikely to
contribute significantly to cardiac nuclear magnetic reso-
nance signals . Although this study is prototypical for clinical
cardiac nuclear magnetic resonance spectroscopy, one should
not assume that these results can be extrapolated to the adult
heart . It is unclear whether or not magnetic field strengths
of 1.5 to 2 tesla are adequate to generate localized high
resolution phosphorus or carbon spectra from the thorax in
a reasonable time period. However, if feasible, it would be
of enormous importance to be able to study cardiac metab-
olism serially over time during myocardial ischemia, either
induced by interventions or occurring naturally during un-
stable ischemic heart disease.
in contrast to the previously described clinical studies.
the investigation by Whitman et al. (9) demonstrates that
phosphorus-3i nuclear magnetic resonance spectroscopy
can be utilized to evaluate manipulations of dietary and
circulating substrates. In the infant described in this study,
marked improvement in the phosphocreatine to inorganic
phosphate ratio was achieved by administration of intra-
venous glucose and a high glucose/medium chain triglyc-
eride meal. Although phosphorus-31 nuclear magnetic res-
onance spectroscopic methods appear to be well suited to
monitor relative changes in the concentrations of nuclear
magnetic resonance-sensitive metabolites, at present they
are not highly quantitative, which represents one of the
major strengths of positron emission tomography (2).
Future Role of Nuclear Magnetic Resonance
in Clinical Cardiology
Nuclear magnetic resonance techniques for imaging and
spectroscopy are still in their infancy. Although exquisite
morphologic detail is achievable with gated nuclear mag-
netic resonance imaging of the heart, the ultimate role for
cardiac nuclear magnetic resonance studies in clinical car-
diology has yet to be defined (23,24). However, the great
potential of nuclear magnetic resonance should not be lim-
ited to providing better anatomic assessment of the heart,
but rather in the evaluation of myocardial metabolism in a
spectrum of pathologic states. Whether this can be accom-
plished with nuclear magnetic resonance and brought from
an investigational technique to a clinically relevant modality
remains to be seen . It is hoped that the development of
nuclear magnetic resonance will provide new insights into
cardiac pathophysiology and alter the ways in which clinical
problems are approached. Nuclear magnetic resonance spec-
troscopy, if successfully applied to adult cardiac disease,
should have a major impact on cardiology . In the past,
cardiac imaging techniques were predominantly concerned
with diagnosis. The pendulum has shifted toward the study
of cardiovascular physiology and the functional assessment
of patients with known disease. In the future, it is likely
that the emphasis will move further toward in vivo study
of myocardial biochemistry. Which of the techniques de-
lACC Vol. 5, NO.3
March 1985:750-3
BERGERAND PETTIGREW
EDITORIAL COMMENT
753
scribed, nuclear magnetic resonance or positron emission
tomography, will predominate in the long-term cannot be
predicted at this time. Currently, positron emission tomog-
raphy imaging represents the leading technique for the study
of myocardial metabolism. It is likely that both methods
will undergo further development and wider availability and
that the major emphasis of cardiovascular imaging in the
future will be in the study of cardiac metabolism by multiple
modalities.
References
I. Jacobus WE, Ingwall JS. Heart Creatine Kinase: The Integration of
Isozymes for Energy Distribution. Baltimore: Williams and Wilkins,
1980.
2. Phelps ME, Schelberg HR, Mazziotta JC. Positron computed tomog-
raphy for studies of myocardial and cerebral function. Ann Intern Med
1983;98:339-59.
3. Berger HJ, Eisner RL, DePuey EG, Patterson R. New vistas in car-
diovascular nuclear medicine. J Nucl Med 1984;25:1254-8.
4. Sobel BE, Geltman EM, Tiefenbrunn AJ, et al. Improvement of re-
gional myocardial metabolism after coronary thrombolysis induced
with tissue type plasmogen activator or streptokinase. Circulation
1984;69:983-90.
5. Geltman EM, Smith JL, Beecher D, Ludbrook PA, Ter-Pogossian
MM, Sobel BE. Altered regional myocardial metabolism in congestive
cardiomyopathy detected by positron tomography. Am J Med
1983;74:773-85.
6. Perloff JK, Henze E, Schelbert HR. Alterations in regional myocardial
metabolism, perfusion, and wall motion in Duchenne muscular dys-
trophy studied by radionuclide imaging. Circulation 1984;69:33-42.
7. Osbakken M, Briggs RW. Nuclear magnetic resonance: theory and
review of cardiac applications. Am Heart J 1984;108:574-90.
8. Pykett IL. NMR imaging in medicine. Sci Am 1982;246:78-88.
9. Whitman GJR, Chance B, Bode H, et al. Diagnosis and therapeutic
evaluation of a pediatric case of cardiomyopathy using phosphorus-
31 nuclear magnetic resonance spectroscopy. J Am Coll Cardiol
1985;5:745-9.
10. Burt CT, Koutcher JA. Multinuclear NMR studies of naturally oc-
curring nuclei. J Nucl Med 1984;25:237-48.
I I. Nunnally RL. In vivo monitoring of metabolism with nuclear magnetic
resonance spectroscopy. Semin Nucl Med 1983;13:377-82.
12. Maudsley AA, Hilal SK, Simon HE, Wittekoek S. In vivo MR spec-
troscopic imaging with P-3!. Radiology 1984;153:745-50.
13. Alger JR, Sillerud LO, Behar KL, et al. In vivo carbon-13 nuclear
magnetic resonance studies in mammals. Science 1981;214:660-2.
14. Bottomley PA, Hart HR, Edelstein WA, et al. NMR imag-
ing/spectroscopy system to study both anatomy and metabolism. Lan-
cet 1983;1:273-4.
15. Neurohr KJ, Gollin G, Barett EJ, Rothman DL, Shulman RG. In vivo
carbon-l J nuclear magnetic resonance studies of heart metabolism
(abstr). Mag Res Med 1984;1:214-5.
16. Neurohr KJ, Gollin G, Barrett EJ, Shulman RG. In vivo 31-P NMR
studies of myocardial high-energy phosphate metabolism during an-
oxia and recovery (abstr). Mag Res Med 1984;1:215-6.
17. Ross BD, Radda GK, Gadian DG, Rocker G, Esiri M, Falconer-Smith
J. Examination of a case of suspected McArdle's syndrome by 31P
nuclear magnetic resonance. N Engl J Med 1981;304:1338-42.
18. Gadian D, Ross B, Bore P, et al. Examination of a myopathy by
phosphorus nuclear magnetic resonance. Lancet 1981;2:774-5.
19. Newman RJ, Bore PJ, Chan L, et al. Nuclear magnetic resonance
studies of forearm muscle in Duchenne dystrophy. Br Med J
1982;284:1072-4.
20. Cady EB, Dawson MJ, Hope PL, et al. Non-invasive investigation
of cerebral metabolism in newborn infants by phosphorus nuclear
magnetic resonance spectroscopy. Lancet 1983;2:1059-62.
21. Bottomley PA, Hart HR, Edelstein WA, et al. Anatomy and metab-
olism of the normal human brain studied by magnetic resonance at
1.5 tesla. Radiology 1984;150:441-6.
22. Hilal SK, Maudsley AA, Simon HE, et al. In vivo NMR imaging of
tissue sodium in the intact cat before and after acute cerebral stroke.
Am J Neuroradiol 1983;4:245-9.
23. van Dijk P. Direct cardiac NMR imaging of heart wall and blood flow
velocity. J Comput Assist Tomogr 1984;8:429-436.
24. McNamara MT, Higgins CB. Cardiovascular applications of magnetic
resonance imaging. Mag Res Imaging 1984;2:167-86.
